Over the past five decades, remarkable strides have been made in the modalities used to treat pediatric cancer. As a result, more than 80 percent of children diagnosed with cancer today can now expect to be cured, joining a rapidly growing population of survivors already now decades from their cancer therapy. Research with this population of patients is an integral part of the cancer continuum and an important part of the mission of CHOP's Cancer Survivorship Program. It is important to not only identify and describe the treatment-related late effects that current survivors face but also to help to design interventions that can potentially mitigate or minimize the long term toxicities associated with current therapies. The Cancer Survivorship Program at CHOP champions an active research agenda, coordinating more than 20 protocols, both as part of cooperative group studies and also investigator initiated protocols. Areas of research focus include: cardiac and pulmonary late effects as well as other health related outcomes, psychological and family functioning, bone health, transition issues, neurocognitive outcomes and fertility preservation for males and females facing cancer therapy.